MedTrace Logo

Safety and Tolerability of Repeat Courses of IM Alefacept

NCT00233662 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2023-08-23

No results posted yet for this study

Summary

The purpose of this study is to determine whether repeat courses of alefacept, administered intramuscularly, are safe when given to chronic plaque psoriasis patients who are receiving standard dermatology treatments.

Conditions

  • Chronic Plaque Psoriasis

Interventions

DRUG

Alefacept

Sponsors & Collaborators

Principal Investigators

  • Barry Ticho, MD · Biogen

  • Kenneth Gordon, MD · Loyola University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-01
Completion
2005-12-01

Countries

  • United States
  • Austria
  • Canada
  • Denmark
  • France
  • Germany
  • Netherlands
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233662 on ClinicalTrials.gov